Cas:20939-16-6 4-amino-3-ethyl-1H-1,2,4-triazole-5-thione manufacturer & supplier

Chemical Name:4-amino-3-ethyl-1H-1,2,4-triazole-5-thione

CAS.NO:20939-16-6

Synonyms:4-amino-3-ethyl-5-mercapto-1,2,4-triazole;4-amino-3-ethyl-1,2,4-triazole-2-thiol;4-amino-5-ethyl-1,2,4-triazole-3-thiol;4-amino-3-ethyl-1,2,4-triazole-5-thione;4-Amino-5-ethyl-4H-[1,2,4]triazole-3-thiol;3-mercapto-4-amino-5-ethyl-1,2,4-triazole;4-amino-5-ethyl-3-mercapto-4H-1,2,4-triazole

Molecular Formula:C₄H₈N₄S

Molecular Weight:144.19800

HS Code:2933990090

Physical and Chemical Properties:

Melting point:184ºC

Boiling point:213.7ºC at 760 mmHg

Density:1.55g/cm3

Index of Refraction:1.741

PSA:91.72000

Exact Mass:144.04700

LogP:0.79810

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-amino-3-ethyl-5-mercapto-1,2,4-triazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-amino-5-ethyl-3-mercapto-4H-1,2,4-triazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-amino-3-ethyl-1,2,4-triazole-5-thione Use and application,4-amino-5-ethyl-3-mercapto-4H-1,2,4-triazole technical grade,usp/ep/jp grade.

Related News: The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 4-amino-3-ethyl-1H-1,2,4-triazole-5-thione manufacturer Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system. 4-amino-3-ethyl-1H-1,2,4-triazole-5-thione supplier The FDA said its decision allows for the J&J doses to be used in the United States or exported. T 4-amino-3-ethyl-1H-1,2,4-triazole-5-thione vendor Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. 4-amino-3-ethyl-1H-1,2,4-triazole-5-thione factory The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).